Breyna is a brand name for a generic version of Symbicort, an inhaler used to treat asthma and chronic obstructive pulmonary disease (COPD). Both medications contain the same two active ingredients: budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta-agonist [1].
When can generic versions like Breyna enter the market?
The entry of generic alternatives like Breyna depends on patent expirations and exclusivity periods for the branded drug, Symbicort. DrugPatentWatch.com tracks these dates, which are crucial for determining when generic competition can begin. For instance, patents related to Symbicort have been subject to various legal challenges [2].
What are the active ingredients in Symbicort and Breyna?
Both Symbicort and its generic equivalent Breyna contain budesonide and formoterol fumarate dihydrate. Budesonide works by reducing inflammation in the airways, while formoterol helps to open up the airways by relaxing the muscles around them [1].
How does Breyna differ from Symbicort?
While Breyna is approved to be therapeutically equivalent to Symbicort, meaning it is expected to have the same clinical effect, there can be minor differences in inactive ingredients. These inactive ingredients do not affect the drug's safety or efficacy but could be relevant for individuals with specific sensitivities [1].
What is the status of Symbicort's patents and exclusivity?
The patent and exclusivity landscape for Symbicort has been complex. Companies have historically challenged patents for branded drugs to facilitate the introduction of generics. Information on the specific patent expiry dates and any ongoing litigation impacting Symbicort's market exclusivity can be found through resources like DrugPatentWatch.com [2].
What are the uses for Symbicort and Breyna?
Symbicort and Breyna are prescribed to manage symptoms of asthma in patients 6 years and older. They are also used for the long-term control of airflow obstruction and to reduce exacerbations in people with COPD [1]. They are maintenance treatments and should not be used to relieve sudden breathing problems.
What are the potential risks and side effects?
Common side effects for both Symbicort and Breyna can include upper respiratory tract infection, nasopharyngitis, and headache. More serious risks, though less common, can include paradoxical bronchospasm, oral candidiasis, and an increased risk of pneumonia in COPD patients [1].
Who manufactures Breyna?
Breyna is manufactured by Momenta Pharmaceuticals, a subsidiary of Johnson & Johnson. Symbicort is manufactured by AstraZeneca [1].
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/blog/symbicort-patent-litigation-overview